GlassScriptPhysician profile
Shannon Madison
NPI 1023428588
$1,789.36
in general payments reported to CMS, 2019-2025
32 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $96.27 · 2021: $254 · 2022: $342 · 2023: $136 · 2024: $440 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.91 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.51 | 2021-2025 | |
| Astellas Pharma US INC | $181.18 | 2020-2024 | Veozah |
| Covidien LP | $150.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.17 | 2022-2025 | |
| Biogen, INC. | $111.18 | 2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $103.24 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $84.97 | 2021 | |
| Organon LLC | $78.64 | 2023-2025 | Nexplanon |
| Exact Sciences Corporation | $66.13 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $60.90 | 2019-2021 | |
| Exeltis, USA INC. | $59.04 | 2022-2024 | Slynd |
| Axonics, INC. | $56.67 | 2022-2023 | Axonics |
| Millicent US INC | $55.07 | 2024-2025 | Intrarosa, Femlyv |
| Daiichi Sankyo INC. | $54.45 | 2020-2023 | Injectafer |
| Aspira Women'S Health INC | $45.91 | 2024 | Ova1 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $35.19 | 2024 | Paragard T 380a, Summit Doppler |
| Mayne Pharma Commercial LLC | $31.14 | 2025 | |
| Bardy Diagnostics, INC. | $30.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Pfizer INC. | $25.77 | 2019 | |
| Shield Therapeutics INC | $25.66 | 2024 | |
| Lilly USA, LLC | $23.14 | 2019-2020 | |
| Novo Nordisk INC | $23.02 | 2021 | |
| Medtronic, INC. | $19.85 | 2023 | Truclear |
| Otsuka America Pharmaceutical, INC. | $19.75 | 2022 | |
| Seqirus USA INC | $18.68 | 2022 | |
| Myovant Sciences INC. | $16.48 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.39 | 2019 | |
| Minerva Surgical, INC | $15.55 | 2025 | |
| Hologic Sales and Service, LLC | $15.10 | 2022 | |
| Evofem Biosciences, INC. | $12.03 | 2022 | |
| Ethicon US, LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Madison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.